ASCO GU 2020 Bladder Cancer - Results from #20

Viewing 21-40 of 46 articles

ASCO GU 2020: Risk Stratification and Management of High-Risk Muscle Invasive Urothelial Carcinoma: Circulating Tumor Cells

ASCO GU 2020: Best of Journals Bladder Cancer - Surgery

ASCO GU 2020: Rucaparib for Recurrent, Locally Advanced, or Metastatic Urothelial Carcinoma: Results from ATLAS, a Phase II Open-Label Trial

ASCO GU 2020: Phase 3 Trial Results - Safety and Efficacy of Intravesical Nadofaragene Firadenovec for patients with High-Grade, BCG Unresponsive Nonmuscle Invasive Bladder Cancer (NMIBC)

ASCO GU 2020: Preliminary Results of the GETUG/AFY VESPER Trial on Toxicity and Pathological Responses

ASCO GU 2020: Discussion on the Phase II NEO-BLADE Trial and BLASST-1 in Muscle Invasive Bladder Cancer (Abstract 438 and 439)

ASCO GU 2020: New Standards in First-Line Therapy for Advanced Disease

ASCO GU 2020: Risk Stratification and Management of High-Risk Muscle Invasive Urothelial Carcinoma: Subtyping

ASCO GU 2020: Phase II Randomized Placebo-Controlled NeoAdjuvant Trial of Nintedanib or Placebo with Gemcitabine and Cisplatin in Locally Advanced Muscle Invasive Bladder Cancer (NEO-BLADE)

ASCO GU 2020: Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of Nivolumab, Gemcitabine, and Cisplatin in Muscle Invasive Bladder Cancer Undergoing Cystectomy

ASCO GU 2020: Risk Stratification and Management of High-Risk Muscle Invasive Urothelial Carcinoma - Circulating Tumor DNA

ASCO GU 2020: Best of Journals Bladder Cancer: From a Medical Oncology Perspective

ASCO GU 2020: Best of the Journals: Urothelial Carcinoma - From the Surgery Perspective

ASCO GU 2020: Options for Bacillus Calmette-Guérin (BCG) Refractory Disease

ASCO GU 2020: Randomized Phase III Trial of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (dd-MVAC) or Gemcitabine and Cisplatin (GC) as Perioperative Chemotherapy for Muscle Invasive Urothelial Bladder Cancer (MIUBC)

ASCO GU 2020: Management Strategies in the Face of the Bacillus Calmette-Guérin Shortage

ASCO GU 2020: Best of Journals Bladder Cancer: Radiation Oncology

ASCO GU 2020: Urothelial Carcinoma from the Perspective of a Radiation Oncologist

ASCO GU 2020: Safety and Efficacy of Intravesical Nadofaragene Firadenovec for patients with High-Grade, BCG Unresponsive Nonmuscle Invasive Bladder Cancer - Phase 3 Trial Results

ASCO GU 2020: Financial Toxicity and Quality of Life: Understanding and Improving Patient Centered Outcomes in Genitourinary Malignancies

1
2
3

email news signup